MBNL3 and non-small cell lung carcinoma: Targeting the miR-302a/muscleblind-like splicing regulator 3 (MBNL3) signal axis, upregulated SBF2-AS1 expression distinctly strengthens NSCLC cell resistance to radiotherapy via reducing the expression of miR-302a [42].